ROS1 expression in invasive ductal carcinoma of the breast related to proliferation activity

Yonsei Medical Journal

Volumn 54, Issue 3, 2013, Pages 650-657

  Eom, Minseob ^a   Lkhagvadorj, Sayamaa ^a   Oh, Sung Soo ^a   Han, Airi ^a   Park, Kwang Hwa ^a  

^a Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Breast; Invasive ductal carcinoma; Prognostic factors; Proliferation rate; ROS1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; MESSENGER RNA;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MITOSIS RATE; ONCOGENE; PAGET NIPPLE DISEASE; PATHOLOGY; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ROS1 ONCOGENE; TISSUE MICROARRAY; TUMOR GROWTH; TUMOR VOLUME;

BREAST; INVASIVE DUCTAL CARCINOMA; PROGNOSTIC FACTORS; PROLIFERATION RATE; ROS1;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SURVIVAL ANALYSIS;

EID: 84875877241     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2013.54.3.650     Document Type: Article

References (28)

1. Birchmeier C, O'Neill K, Riggs M, Wigler M. Characterization of ROS1 cDNA from a human glioblastoma cell line. Proc Natl Acad Sci U S A 1990;87:4799-4803.
2. Chen J, Zong CS, Wang LH. Tissue and epithelial cell-specific expression of chicken proto-oncogene c-ros in several organs suggests that it may play roles in their development and mature functions. Oncogene 1994;9:773-780.
3. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009;1795:37-52.
4. Eom M, Han A, Yi SY, Shin JJ, Cui Y, Park KH. RHEB expression in fbroadenomas of the breast. Pathol Int 2008;58:226-232.
5. Zhao JF, Sharma S. Expression of the ROS1 oncogene for tyro-sine receptor kinase in adult human meningiomas. Cancer Genet Cytogenet 1995;83:148-154.
6. Bonner AE, Lemon WJ, Devereux TR, Lubet RA, You M. Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas. Oncogene 2004;23:1166-1176.
7. Yovchev MI, Grozdanov PN, Joseph B, Gupta S, Dabeva MD. Novel hepatic progenitor cell surface markers in the adult rat liver. Hepatology 2007;45:139-149.
8. Ruhe JE, Streit S, Hart S, Wong CH, Specht K, Knyazev P, et al. Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res 2007;67:11368-11376.
9. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-410.
10. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press; 2003.
11. Kumar B, De Silva M, Venter DJ, Armes JE. Tissue microarrays: a practical guide. Pathology 2004;36:295-300.
12. Park KH, Choi SE, Eom M, Kang Y. Downregulation of the ana-phase-promoting complex (APC)7 in invasive ductal carcinomas of the breast and its clinicopathologic relationships. Breast Cancer Res 2005;7:R238-R247.
13. Dabbs DJ. Diagnostic immunohistochemistry: theranostic and genomic applications. 3rd ed. Philadelphia (PA): Saunders/Elsevier; 2010.
14. Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A 1987;84:9270-9274.
15. Charest A, Kheifets V, Park J, Lane K, McMahon K, Nutt CL, et al. Oncogenic targeting of an activated tyrosine kinase to the Golgi apparatus in a glioblastoma. Proc Natl Acad Sci U S A 2003;100: 916-921.
16. Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H, et al. Fusion of FIG to the receptor tyrosine kinase ROS in a glio-blastoma with an interstitial del(6)(q21q21). Genes Chromosomes Cancer 2003;37:58-71.
17. Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 2011;6:e15640.
18. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifes oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.
19. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements defne a unique molecular class of lung cancers. J Clin Oncol 2012;30:863-870.
20. Rosen PP. Rosen's breast pathology. 3rd ed. Philadelphia (PA): Wolters Kluwer/Lippincott Williams & Wilkins; 2009.
21. Kumar V. Abbas AK, Fausto N, Aster JC. Robbins and Cotran's pathologic basis of disease. 8th ed. Philadelphia (PA): Saunders; 2010.
22. Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957;11:359-377.
23. Meyer JS, Alvarez C, Milikowski C, Olson N, Russo I, Russo J, et al. Breast carcinoma malignancy grading by Bloom-Richardson system vs proliferation index: reproducibility of grade and advantages of proliferation index. Mod Pathol 2005;18:1067-1078.
24. van Diest PJ, van der Wall E, Baak JP. Prognostic value of proliferation in invasive breast cancer: a review. J Clin Pathol 2004;57: 675-681.
25. Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker? Cancer 2003;97:1321-1331.
26. Miglietta L, Vanella P, Canobbio L, Naso C, Cerisola N, Meszaros P, et al. Prognostic value of estrogen receptor and Ki-67 index after neoadjuvant chemotherapy in locally advanced breast cancer expressing high levels of proliferation at diagnosis. Oncology 2010; 79:255-261.
27. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB. Pre-clinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 2012;7:1086-1090.
28. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012; 18:378-381.